Bio-Works Technologies AB (BIOWKS) - Total Assets
Based on the latest financial reports, Bio-Works Technologies AB (BIOWKS) holds total assets worth Skr70.76 Million SEK (≈ $7.61 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Bio-Works Technologies AB (BIOWKS) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Bio-Works Technologies AB - Total Assets Trend (2015–2025)
This chart illustrates how Bio-Works Technologies AB's total assets have evolved over time, based on quarterly financial data. See Bio-Works Technologies AB (BIOWKS) net assets for net asset value and shareholders' equity analysis.
Bio-Works Technologies AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Bio-Works Technologies AB's total assets of Skr70.76 Million consist of 97.6% current assets and 2.4% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 49.4% |
| Accounts Receivable | Skr18.47 Million | 26.1% |
| Inventory | Skr15.64 Million | 22.1% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Bio-Works Technologies AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Bio-Works Technologies AB (BIOWKS) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio-Works Technologies AB's current assets represent 97.6% of total assets in 2025, an increase from 57.6% in 2015.
- Cash Position: Cash and equivalents constituted 49.4% of total assets in 2025, up from 42.1% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 38.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 26.1% of total assets.
Bio-Works Technologies AB Competitors by Total Assets
Key competitors of Bio-Works Technologies AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenyang Xingqi Pharmaceutical Co Ltd
SHE:300573
|
China | CN¥2.42 Billion |
|
Hangzhou Alltest Biotech Co. Ltd. A
SHG:688606
|
China | CN¥4.11 Billion |
|
Daxor Corporation
NASDAQ:DXR
|
USA | $35.90 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
Bio-Works Technologies AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.20 | 6.41 | 5.46 |
| Quick Ratio | 2.48 | 5.13 | 4.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr47.50 Million | Skr42.77 Million | Skr35.86 Million |
Bio-Works Technologies AB - Advanced Valuation Insights
This section examines the relationship between Bio-Works Technologies AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.38 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | 34.8% |
| Total Assets | Skr70.76 Million |
| Market Capitalization | $37.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bio-Works Technologies AB's assets below their book value (0.53x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Bio-Works Technologies AB's assets grew by 34.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bio-Works Technologies AB (2015–2025)
The table below shows the annual total assets of Bio-Works Technologies AB from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr70.76 Million ≈ $7.61 Million |
+34.78% |
| 2024-12-31 | Skr52.50 Million ≈ $5.65 Million |
-15.53% |
| 2023-12-31 | Skr62.15 Million ≈ $6.69 Million |
-32.16% |
| 2022-12-31 | Skr91.61 Million ≈ $9.86 Million |
-24.20% |
| 2021-12-31 | Skr120.86 Million ≈ $13.01 Million |
+165.63% |
| 2020-12-31 | Skr45.50 Million ≈ $4.90 Million |
-48.31% |
| 2019-12-31 | Skr88.02 Million ≈ $9.47 Million |
+30.59% |
| 2018-12-31 | Skr67.41 Million ≈ $7.25 Million |
-35.99% |
| 2017-12-31 | Skr105.31 Million ≈ $11.33 Million |
+275.06% |
| 2016-12-31 | Skr28.08 Million ≈ $3.02 Million |
+13.63% |
| 2015-12-31 | Skr24.71 Million ≈ $2.66 Million |
-- |
About Bio-Works Technologies AB
Bio-Works Technologies AB (publ), together with its subsidiaries, engages in the manufactures and sale of chromatography resins for the purification of biopharmaceuticals in Sweden. The company offers affinity and activated resin, hydrophobic interaction chromatography (HIC) resins, GoBio Mini and GoBio prepacked columns, ion exchange chromatography (IEX) resin, immobilized metal-ion affinity chr… Read more